Stahl N, Yancopoulos G D
Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591.
J Neurobiol. 1994 Nov;25(11):1454-66. doi: 10.1002/neu.480251111.
Recent efforts to understand the mechanism of action of CNTF have led to the identification of a three-component receptor complex for CNTF. The distributions of these receptor components explain the known target cell specificity of CNTF, and have also helped identify new and unexpected targets of CNTF action. In addition to including a CNTF-specific component, known as CNTFR alpha, the CNTF receptor complex utilizes two receptor components, gp130 and LIFR beta, that are shared with members of a family of broadly acting cytokines, including leukemia inhibitory factor (LIF) and interleukin-6 (IL6). The finding that the CNTF receptor complex shares components with this family of cytokines has led to the realization that CNTF should also be considered a cytokine--but one that differs from its relatives in that its actions are largely limited to cells of the nervous system due to the restricted expression of one of its receptor components, CNTFR alpha. CNTFR alpha does not play a direct role in signaling, but instead forms a complex with CNTF that promotes its binding to the signal transducing "beta" receptor components, gp130 and LIFR beta. Thus CNTF utilizes identical signal transducing receptor components in neurons that its relatives use on nonneuronal cells to elicit strikingly dissimilar responses, indicating that different cells interpret the same cell surface signal in dramatically different ways. The three CNTF receptor components are initially unassociated on the cell surface, and are brought together in step-wise fashion upon CNTF binding. CNTF first binds to CNTFR alpha, then recruits gp130, and finally complexes with LIFR beta. It is this last step in complex formation, involving heterodimerization between "beta" components, that activates intracellular signaling. Signal initiation is due to activation of members of a family of cytoplasmic tyrosine kinase, known as the Jak/Tyk kinases, which are preassociated with the beta components in an inactive state and then become activated upon beta component dimerization; the Jak/Tyk kinases, in turn, activate a variety of intracellular signaling molecules, such as members of the STAT family of DNA binding transcriptional activators. A detailed understanding of the mechanism of activation of the CNTF receptor complex has led to the realization that all members of the CNTF family of cytokines activate signaling in much the same way, by inducing either homo- or heterodimerization of beta receptor components and thus activation of the preassociated Jak/Tyk kinases; this mode of receptor activation may prove to be more generally applicable to all cytokine receptors.(ABSTRACT TRUNCATED AT 400 WORDS)
近期对睫状神经营养因子(CNTF)作用机制的研究努力,已促成了一种CNTF三聚体受体复合物的鉴定。这些受体成分的分布解释了CNTF已知的靶细胞特异性,还帮助确定了CNTF作用的新的意外靶点。除了包含一种被称为CNTFRα的CNTF特异性成分外,CNTF受体复合物还利用了两种受体成分,即gp130和LIFRβ,它们与包括白血病抑制因子(LIF)和白细胞介素-6(IL6)在内的一类广泛作用的细胞因子家族成员共享。CNTF受体复合物与该细胞因子家族共享成分这一发现,使人们认识到CNTF也应被视为一种细胞因子——但它与其亲属不同,因其作用主要限于神经系统细胞,这是由于其一种受体成分CNTFRα的表达受限。CNTFRα在信号传导中不发挥直接作用,而是与CNTF形成复合物,促进其与信号转导“β”受体成分gp130和LIFRβ的结合。因此,CNTF在神经元中利用与其亲属在非神经元细胞上使用的相同的信号转导受体成分,引发截然不同的反应,这表明不同细胞以截然不同的方式解读相同的细胞表面信号。三种CNTF受体成分最初在细胞表面未结合,在CNTF结合后以逐步方式聚集在一起。CNTF首先与CNTFRα结合,然后招募gp130,最后与LIFRβ形成复合物。正是复合物形成的这最后一步,涉及“β”成分之间的异二聚化,激活了细胞内信号传导。信号起始是由于一种被称为Jak/Tyk激酶的细胞质酪氨酸激酶家族成员的激活,这些激酶在非活性状态下与β成分预先结合,然后在β成分二聚化时被激活;Jak/Tyk激酶进而激活多种细胞内信号分子,如DNA结合转录激活因子STAT家族成员。对CNTF受体复合物激活机制的详细了解,使人们认识到CNTF细胞因子家族的所有成员都以大致相同的方式激活信号传导,即通过诱导β受体成分的同二聚化或异二聚化,从而激活预先结合的Jak/Tyk激酶;这种受体激活模式可能被证明更普遍适用于所有细胞因子受体。(摘要截断于400字)